Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for Amphastar Pharmaceuticals (AMPH) over the last 7 years, with Q3 2025 value amounting to $885000.0.

  • Amphastar Pharmaceuticals' Amortization of Deferred Charges rose 1895.16% to $885000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 6091.72%. This contributed to the annual value of $6.0 million for FY2024, which is 4708.31% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Amortization of Deferred Charges of $885000.0 as of Q3 2025, which was up 1895.16% from $842000.0 recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Amortization of Deferred Charges peaked at $5.2 million during Q3 2023, and registered a low of -$2.3 million during Q4 2021.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $826000.0 (2021), whereas its average is $1.2 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Amortization of Deferred Charges tumbled by 33458.33% in 2021 and then soared by 961000.0% in 2023.
  • Amphastar Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at -$2.3 million in 2021, then surged by 101.33% to $30000.0 in 2022, then soared by 9610.0% to $2.9 million in 2023, then tumbled by 75.15% to $724000.0 in 2024, then increased by 22.24% to $885000.0 in 2025.
  • Its last three reported values are $885000.0 in Q3 2025, $842000.0 for Q2 2025, and $762000.0 during Q1 2025.